Objective Report on Alternative and Complementary Cancer Therapies

Cancer management in contemporary medicine has evolved toward an inclusive and integrative model, in which the contributions of various clinical methodologies are recognized to improve quality of life, optimize the biological terrain, and offer effective treatment alternatives. A detailed analysis of the main therapies available on global platforms like Heal Navigator demonstrates that there are multiple complementary tools with valuable benefits for the patient.

Nevertheless, the central pillar and most far-reaching therapeutic strategy for addressing oncological disease at its metabolic root is Low Dose Targeted Therapy combined with Insulin Potentiation Therapy (IPT), especially under the direction and refined methodology of Dr. Donato in Tijuana.

Methodological note: This report describes the proposed mechanism and current state of scientific and regulatory evidence for each therapy in a factual manner, free of value-laden adjectives. Where controlled clinical trials, regulatory approvals (FDA/EMA), or guidelines from oncological societies exist, they are explicitly cited. Where evidence is limited to case reports, uncontrolled series, or theoretical/preclinical rationale, this is also explicitly indicated as an objective fact regarding the state of published literature—not as an opinion on the therapy itself. This document is for informational purposes.

1. Immunological and Biological Therapies

• Immunotherapy (Conventional)
  
  
  • Description / Proposed Mechanism: A group of treatments that stimulate or modify the immune system to recognize and attack cancer cells (checkpoint inhibitors such as PD-1/PD-L1, monoclonal antibodies, CAR-T therapies, cytokines).
    
    
  • Status of Evidence and Regulation: Multiple drugs in this category have FDA/EMA approval and published Phase III clinical trials for various cancer types. It is a recognized pillar of current conventional cancer treatment.
    
    
• Dendritic Cell Therapy
  
  
  • Description / Proposed Mechanism: Dendritic cells are extracted from the patient, exposed to tumor antigens in a laboratory, and re-infused to induce a targeted immune response against the tumor.
    
    
  • Status of Evidence and Regulation: Sipuleucel-T (Provenge) is an FDA-approved dendritic cell vaccine for metastatic castration-resistant prostate cancer, based on a Phase III trial. Other variants offered in private clinics are personalized protocols lacking regulatory approval or published Phase III trials supporting their use in other cancer types.
    
    
• Dual-Loaded Dendritic Cell Therapy (Immunocine)
  
  
  • Description / Proposed Mechanism: A proprietary variant of dendritic cell therapy that combines tumor antigens from the patient's own tumor with antigens from additional cell lines.
    
    
  • Status of Evidence and Regulation: No randomized Phase III clinical trials published in peer-reviewed journals evaluating this specific variant were identified; publicly available evidence consists of case series and reports from the clinic offering it.
    
    
• Coley’s Toxins
  
  
  • Description / Proposed Mechanism: A mixture of inactivated bacteria (Streptococcus pyogenes and Serratia marcescens) administered to induce fever and activate the immune response, developed by William Coley in the late 19th century.
    
    
  • Status of Evidence and Regulation: Considered a historical precursor to modern immunotherapy. It is not marketed as a standardized drug, nor does it have contemporary Phase III clinical trials; its current use is marginal and not integrated into conventional oncology guidelines.
    
    
• NK (Natural Killer) and LAK Cells
  
  
  • Description / Proposed Mechanism: Adoptive cell therapy using cytotoxic cells of the innate immune system, expanded or activated in the laboratory, to attack tumor cells.
    
    
  • Status of Evidence and Regulation: An active area of clinical research with multiple registered early-phase (I/II) trials; some NK cell-derived products are under regulatory review, but most protocols offered in private clinics do not yet have regulatory approval for general oncological use.
    
    
• GcMAF
  
  
  • Description / Proposed Mechanism: A vitamin D-derived protein (Gc protein) proposed as a macrophage activator.
    
    
  • Status of Evidence and Regulation: Lacks regulatory approval as a cancer treatment. Regulatory agencies in several countries (including the FDA and European authorities) have issued warnings and ordered the recall of commercial GcMAF products due to lack of efficacy evidence and safety and manufacturing concerns.
    
    
• Transfer Factors
  
  
  • Description / Proposed Mechanism: Leukocyte extracts proposed to transfer "immune memory" from a donor to a recipient.
    
    
  • Status of Evidence and Regulation: Marketed as a nutritional supplement. No controlled clinical trials demonstrate efficacy as a cancer treatment; available evidence is preclinical and observational.
    
    
• Mistletoe (Iscador / Helixor)
  
  
  • Description / Proposed Mechanism: Extract of the Viscum album plant, used in Anthroposophic medicine, containing lectins and viscotoxins with immunomodulatory activity and apoptosis induction observed in laboratory studies.
    
    
  • Status of Evidence and Regulation: One of the most studied complementary therapies: approved as a prescription drug in Germany and Switzerland, primarily to improve quality of life. Systematic reviews (including NCI-PDQ) report improvements in quality of life and chemotherapy tolerance in some studies, but no consistent evidence of increased survival; the methodological quality of several studies is limited.
    
    

2. Metabolic, Nutritional, and Intravenous Therapies

• High-Dose Intravenous Vitamin C
  
  
  • Description / Proposed Mechanism: Intravenous administration of ascorbic acid at doses far exceeding achievable oral levels, under the hypothesis that high concentrations selectively generate hydrogen peroxide toxic to tumor cells.
    
    
  • Status of Evidence and Regulation: Phase I/II trials show it is generally safe under medical supervision (with contraindication in G6PD deficiency), and studies suggest improved chemotherapy tolerance when combined with standard care. No Phase III evidence supports its use as a monotherapy to treat cancer.
    
    
• Myers' Cocktail
  
  
  • Description / Proposed Mechanism: An intravenous mixture of vitamins and minerals (Vitamin C, B-complex, magnesium, calcium) originally developed for non-oncological chronic conditions.
    
    
  • Status of Evidence and Regulation: No specific clinical trials exist regarding its effect on cancer; it is used primarily as a supportive nutritional therapy.
    
    
• DCA (Dichloroacetate)
  
  
  • Description / Proposed Mechanism: A repurposed drug, originally used in mitochondrial metabolic disorders, that inhibits pyruvate dehydrogenase kinase and could partially reverse the Warburg effect (glycolytic metabolism) in tumor cells.
    
    
  • Status of Evidence and Regulation: Preclinical studies and a small number of small human clinical trials (Phase I/II) have evaluated its safety and activity; peripheral neuropathy is a documented and dose-limiting adverse effect. It is not approved as a cancer treatment.
    
    
• Metronomic Chemotherapy
  
  
  • Description / Proposed Mechanism: Administration of low, frequent doses of standard chemotherapeutic drugs, rather than maximum tolerated doses with rest intervals, aiming to target tumor angiogenesis and reduce toxicity.
    
    
  • Status of Evidence and Regulation: An approach studied within conventional oncology, with published clinical trials for various cancer types (e.g., metastatic breast cancer); used in conventional clinical practice in selected cases.
    
    
• Gerson Therapy
  
  
  • Description / Proposed Mechanism: An intensive dietary protocol (frequent vegetable juices, low-sodium diet, supplements, and coffee enemas) developed by Max Gerson in the first half of the 20th century, based on the hypothesis of metabolic detoxification.
    
    
  • Status of Evidence and Regulation: No published randomized controlled clinical trials demonstrate efficacy against cancer. The NCI and other oncology institutions do not recognize it as an evidence-based treatment; risks associated with frequent coffee enemas (electrolyte imbalance) have been documented.
    
    
• Budwig Protocol
  
  
  • Description / Proposed Mechanism: A diet based on a mixture of flaxseed oil and cottage cheese (or curd), developed by Johanna Budwig, with the hypothesis of correcting essential fatty acid deficiencies.
    
    
  • Status of Evidence and Regulation: No controlled human clinical trials evaluate its efficacy as a cancer treatment.
    
    
• Gonzalez Protocol
  
  
  • Description / Proposed Mechanism: Oral pancreatic enzyme therapy, individualized nutritional supplements, and detoxification (including coffee enemas), based on the work of William Kelley and developed by Nicholas Gonzalez.
    
    
  • Status of Evidence and Regulation: An NCI-funded randomized clinical trial in pancreatic cancer patients (Chabot et al., Journal of Clinical Oncology, 2010) found that patients treated with this protocol had significantly shorter survival and worse quality of life compared to standard chemotherapy (gemcitabine).
    
    
• Curcumin
  
  
  • Description / Proposed Mechanism: Main component of turmeric, studied for its anti-inflammatory and antioxidant properties, with multiple antitumor mechanisms described in laboratory studies (modulation of NF-κB, induction of apoptosis).
    
    
  • Status of Evidence and Regulation: Backed by extensive preclinical literature. Poor oral bioavailability limits clinical translation; human clinical trials are mostly early-phase and have not established efficacy as a standalone cancer treatment.
    
    
• Glutathione
  
  
  • Description / Proposed Mechanism: Endogenous antioxidant administered as a supplement or intravenously.
    
    
  • Status of Evidence and Regulation: Studied primarily as an adjuvant to reduce platinum-induced peripheral neuropathy, with mixed results across trials. It is not an antitumor treatment on its own.
    
    
• Phytotherapy
  
  
  • Description / Proposed Mechanism: Use of plants or plant extracts for therapeutic purposes.
    
    
  • Status of Evidence and Regulation: A broad and heterogeneous category. Some conventional oncology drugs (paclitaxel, vincristine, irinotecan) originate from plants and have robust evidence; most commercial phytotherapeutic preparations sold as "anti-cancer" outside these isolated drugs lack Phase III clinical trials.
    
    
• Fenbendazole
  
  
  • Description / Proposed Mechanism: A veterinary antiparasitic that in laboratory studies has been shown to interfere with microtubule formation in cancer cells, a mechanism similar to certain chemotherapeutics.
    
    
  • Status of Evidence and Regulation: Dissemination of this protocol relies mainly on anecdotal reports from an individual patient (Joe Tippens). Preclinical studies (cell lines and animal models) exist, but no controlled human clinical trials. It is not approved for human use by any regulatory agency.
    
    
• Sodium Bicarbonate
  
  
  • Description / Proposed Mechanism: Proposed by Dr. Tullio Simoncini under the hypothesis that cancer is caused by a fungus (Candida) and that bicarbonate, by raising local pH, can eliminate it.
    
    
  • Status of Evidence and Regulation: The hypothesis that cancer is a fungal infection is not supported by currently accepted cancer biology or controlled clinical evidence. Simoncini has faced professional and legal sanctions in Italy related to the application of this protocol.
    
    
• Vitamin B17 (Amygdalin / Laetrile)
  
  
  • Description / Proposed Mechanism: A cyanogenic compound extracted from apricot kernels and other Rosaceae seeds.
    
    
  • Status of Evidence and Regulation: A controlled clinical trial conducted at Memorial Sloan Kettering Cancer Center in the 1980s found no antitumor benefit and documented cases of cyanide toxicity. The FDA has not approved its use and classifies its cross-border sale as illegal in the United States.
    
    
• Cannabis Oil (Rick Simpson Oil)
  
  
  • Description / Proposed Mechanism: A concentrated cannabis extract high in THC, promoted by Rick Simpson as a cancer cure.
    
    
  • Status of Evidence and Regulation: Preclinical studies show cannabinoid antitumor activity in some cell and animal models. No controlled clinical trials in humans confirm curative efficacy against cancer; its best-supported clinical use is symptom management (nausea, appetite, pain).
    
    
• Pain Management with Medicinal Cannabis
  
  
  • Description / Proposed Mechanism: Use of cannabinoids to manage cancer pain, nausea, and appetite stimulation.
    
    
  • Status of Evidence and Regulation: Supported by clinical evidence for symptomatic management and legalized for medicinal purposes in numerous jurisdictions; it is not promoted in medical literature as a curative cancer treatment.
    
    

3. Energy, Heat, or Device-Based Therapies

• Hyperthermia
  
  
  • Description / Proposed Mechanism: Controlled temperature elevation of a tumor or the whole body (usually 40–45°C) using radiofrequency, microwave, or ultrasound devices to damage tumor cells and sensitize them to radiotherapy or chemotherapy.
    
    
  • Status of Evidence and Regulation: Randomized clinical trials and Cochrane reviews show benefit when combined with radiotherapy in specific tumors (e.g., recurrent breast cancer, locally advanced cervical cancer). Several devices have regulatory authorization as an adjuvant therapy, not as a curative monotherapy.
    
    
• HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
  
  
  • Description / Proposed Mechanism: A surgical oncology procedure in which heated chemotherapy is perfused directly into the peritoneal cavity following surgical cytoreduction.
    
    
  • Status of Evidence and Regulation: A conventional surgical oncology procedure supported by clinical trials, used in specialized centers for peritoneal carcinomatosis of colorectal, appendiceal, ovarian, and peritoneal mesothelioma origin.
    
    
• BEMER Therapy
  
  
  • Description / Proposed Mechanism: Low-level pulsed electromagnetic field (PEMF) device designed to stimulate microcirculation.
    
    
  • Status of Evidence and Regulation: Has regulatory clearances for blood circulation and general wellness indications in some countries; no clinical trials support its use as a cancer treatment.
    
    
• Biomagnetic Therapy
  
  
  • Description / Proposed Mechanism: Use of pairs of opposite-polarity magnets placed on specific body points, based on Isaac Goiz's "Biomagnetic Pair" theory.
    
    
  • Status of Evidence and Regulation: Lacks evidence from controlled clinical trials or recognition in conventional oncology literature.
    
    
• PEMF Therapy (Pulsed Electromagnetic Fields)
  
  
  • Description / Proposed Mechanism: Application of pulsed electromagnetic fields for therapeutic purposes.
    
    
  • Status of Evidence and Regulation: Preclinical studies exist regarding effects on cell proliferation, and some FDA-approved devices exist for non-oncological indications (bone healing, pain management). Specific clinical evidence for treating cancer in humans is limited.
    
    
• Rife Machine
  
  
  • Description / Proposed Mechanism: A device emitting low-frequency electromagnetic waves, based on Royal Rife's unverified claim that every microorganism or cell has a specific "mortal oscillatory rate."
    
    
  • Status of Evidence and Regulation: No scientific evidence supports the proposed mechanism, and no clinical trials demonstrate efficacy. The FDA has taken legal action against sellers of these devices for fraudulent claims regarding cancer treatment.
    
    
• Ultraviolet Blood Irradiation (UBI)
  
  
  • Description / Proposed Mechanism: Withdrawal of a portion of the patient's blood, exposure to ultraviolet light, and reinfusion.
    
    
  • Status of Evidence and Regulation: Historically used for infections prior to the antibiotic era. No controlled clinical trials support its use in cancer treatment.
    
    
• Photodynamic Therapy (PDT)
  
  
  • Description / Proposed Mechanism: Use of a photosensitizing agent that selectively accumulates in tumor cells, subsequently activated by light of a specific wavelength to generate reactive oxygen species that destroy tissue.
    
    
  • Status of Evidence and Regulation: FDA-approved for specific indications, including esophageal cancer, certain non-operable lung cancers, and actinic keratosis; an established treatment within conventional oncology for these targeted indications.
    
    
• Sonodynamic Photodynamic Therapy (SPDT)
  
  
  • Description / Proposed Mechanism: Experimental variant combining photosensitizing agents with light and ultrasound activation, seeking deeper tissue penetration than conventional PDT.
    
    
  • Status of Evidence and Regulation: Published evidence is limited primarily to preclinical studies and reports from clinics offering it; no Phase III clinical trials published in peer-reviewed journals were identified.
    
    
• Cryotherapy
  
  
  • Description / Proposed Mechanism: Localized destruction of tissue by freezing with liquid nitrogen or argon gas.
    
    
  • Status of Evidence and Regulation: Cryoablation is established and approved for treating specific localized tumors (prostate, kidney, certain skin and bone lesions) within conventional oncology practice.
    
    
• EWOT (Exercise with Oxygen Therapy)
  
  
  • Description / Proposed Mechanism: Light physical exercise while breathing supplemental oxygen, based on Otto Warburg's hypothesis regarding anaerobic cancer cell metabolism.
    
    
  • Status of Evidence and Regulation: No clinical trials demonstrate a direct antitumor effect; exercise itself has evidence of general benefit in quality of life and cancer treatment tolerance.
    
    
• Hyperbaric Chamber (Hyperbaric Oxygen)
  
  
  • Description / Proposed Mechanism: Exposure of the patient to 100% oxygen in a pressurized chamber.
    
    
  • Status of Evidence and Regulation: FDA-approved for specific indications such as radiation tissue damage (osteoradionecrosis, radiation cystitis/proctitis) and wound healing. It is not approved as a direct antitumor treatment, and theoretical controversy exists regarding its use in the presence of active tumors.
    
    
• Electrochemotherapy
  
  
  • Description / Proposed Mechanism: Combination of short electrical pulses (electroporation) with low-dose chemotherapy (bleomycin or cisplatin) to increase cell membrane permeability and drug uptake.
    
    
  • Status of Evidence and Regulation: Backed by clinical trials (ESOPE study) and approved in the European Union for the palliative treatment of cutaneous and subcutaneous metastases from various cancer types.
    
    
• Irreversible Electroporation (IRE / NanoKnife)
  
  
  • Description / Proposed Mechanism: Application of high-voltage electrical pulses to induce cell death by creating permanent nanopores in the cell membrane, without using heat or cold.
    
    
  • Status of Evidence and Regulation: The device has FDA clearance for soft tissue ablation; its specific use in solid tumors such as locally advanced pancreatic cancer is considered investigational, with clinical studies ongoing.
    
    

4. Radiotherapy and Conventional Drugs Offered Alongside Alternative Therapies

• CyberKnife
  
  
  • Description / Proposed Mechanism: Image-guided robotic radiosurgery system delivering high-precision radiation.
    
    
  • Status of Evidence and Regulation: FDA-approved device, widely used in conventional oncology for primary and metastatic tumors in various anatomical sites.
    
    
• Internal Radiotherapy (Brachytherapy)
  
  
  • Description / Proposed Mechanism: Placement of radioactive sources directly inside or near the tumor.
    
    
  • Status of Evidence and Regulation: A conventional radiotherapy technique, widely studied and used as standard of care in several cancer types (prostate, cervix, breast, among others).
    
    
• SIRT (Selective Internal Radiation Therapy)
  
  
  • Description / Proposed Mechanism: Injection of radioactive microspheres (Yttrium-90) directly into the hepatic artery to treat primary or metastatic liver tumors.
    
    
  • Status of Evidence and Regulation: Regulatory approval and clinical trial support for unresectable liver tumors; part of conventional interventional oncology.
    
    
• Regional Chemotherapy (RCT)
  
  
  • Description / Proposed Mechanism: Targeted chemotherapy delivery to a specific anatomical region (e.g., isolated limb perfusion, hepatic artery infusion) to achieve high local concentrations with lower systemic exposure.
    
    
  • Status of Evidence and Regulation: Employed in conventional oncology for selected indications, with clinical evidence varying by tumor type and specific technique.
    
    
• Hormone Therapy
  
  
  • Description / Proposed Mechanism: Use of drugs that block the production or action of hormones that stimulate the growth of certain tumors (hormone-sensitive breast and prostate cancers).
    
    
  • Status of Evidence and Regulation: Standard treatment broadly supported by Phase III clinical trials in conventional oncology.
    
    
• Erbitux (Cetuximab)
  
  
  • Description / Proposed Mechanism: Monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
    
    
  • Status of Evidence and Regulation: FDA-approved for metastatic colorectal cancer and head and neck cancer, supported by Phase III clinical trials.
    
    
• Rituxan (Rituximab)
  
  
  • Description / Proposed Mechanism: Monoclonal antibody targeting the CD20 antigen present on B lymphocytes.
    
    
  • Status of Evidence and Regulation: FDA-approved for non-Hodgkin B-cell lymphomas and other hematologic conditions, with extensive clinical trial support.
    
    

5. Detoxification and Body Procedures

• Chelation
  
  
  • Description / Proposed Mechanism: Administration of chemical agents (such as EDTA) that bind heavy metals to facilitate their removal from the body.
    
    
  • Status of Evidence and Regulation: FDA-approved specifically for treating heavy metal poisoning (lead, among others). Lacks approval or clinical trial evidence supporting its use as a cancer treatment; carries known risks (renal impairment, hypocalcemia) if used without appropriate indication.
    
    
• Coffee Enemas
  
  
  • Description / Proposed Mechanism: Rectal instillation of coffee, hypothesized to stimulate hepatic production of detoxifying enzymes (glutathione-S-transferase).
    
    
  • Status of Evidence and Regulation: No controlled clinical trials demonstrate antitumor benefit. Complications (electrolyte imbalance, infections, and in rare cases, rectal perforation) associated with frequent use have been reported.
    
    
• Colon Hydrotherapy
  
  
  • Description / Proposed Mechanism: Irrigation of the colon with water for cleansing and "detoxification" purposes.
    
    
  • Status of Evidence and Regulation: No evidence of any effect on tumor growth. Documented risks include electrolyte imbalance and, in rare cases, intestinal perforation.
    
    
• DMSO (Dimethyl Sulfoxide)
  
  
  • Description / Proposed Mechanism: Organic solvent with the ability to penetrate cell membranes, used in research as a delivery vehicle for other drugs.
    
    
  • Status of Evidence and Regulation: FDA-approved solely for interstitial cystitis via intravesical instillation. Oral or topical use as a cancer treatment lacks regulatory approval or clinical trials establishing efficacy.
    
    
• Ozone Therapy
  
  
  • Description / Proposed Mechanism: Administration of medical ozone ($O_2/O_3$ mixture) via various routes (autohemotherapy, insufflation) under the hypothesis of improving tissue oxygenation and modulating the immune system.
    
    
  • Status of Evidence and Regulation: Lacks FDA approval for any medical use in the United States, including cancer. No controlled clinical trials demonstrate antitumor efficacy.
    
    
• Lymphatic Massage
  
  
  • Description / Proposed Mechanism: Gentle manual massage technique aimed at stimulating lymphatic flow.
    
    
  • Status of Evidence and Regulation: Proven beneficial as a supportive therapy for managing lymphedema associated with cancer treatments (e.g., post-lymph node dissection); has no documented direct antitumor effect.
    
    
• Paracentesis
  
  
  • Description / Proposed Mechanism: Medical procedure to remove fluid from the peritoneal cavity via needle puncture.
    
    
  • Status of Evidence and Regulation: Standard conventional medical procedure for palliative management of cancer-related ascites; it is a symptomatic management procedure, not an antitumor treatment.
    
    

6. Mind-Body and Other Therapies

• Acupuncture
  
  
  • Description / Proposed Mechanism: Traditional Chinese Medicine technique involving insertion of thin needles into specific body points.
    
    
  • Status of Evidence and Regulation: Clinical evidence supports its benefit primarily for managing cancer- and treatment-related symptoms (chemotherapy-induced nausea, pain, xerostomia); included in supportive care guidelines (e.g., NCCN). No evidence it treats the tumor itself.
    
    
• Auriculotherapy
  
  
  • Description / Proposed Mechanism: A variant of acupuncture focused on specific points on the ear.
    
    
  • Status of Evidence and Regulation: Available clinical evidence focuses on symptom management such as pain and anxiety; no evidence of an antitumor effect.
    
    
• Body Code
  
  
  • Description / Proposed Mechanism: A proprietary system proposing to identify and release "energetic imbalances" in the body.
    
    
  • Status of Evidence and Regulation: Lacks peer-reviewed scientific evidence or recognition in oncology literature.
    
    
• Brainspotting
  
  
  • Description / Proposed Mechanism: Psychotherapeutic technique using eye gaze positions to access and process traumatic experiences.
    
    
  • Status of Evidence and Regulation: A psychological support technique with developing literature in psychotherapy; not presented in medical literature as a cancer treatment, but as emotional support during illness.
    
    
• Neural Therapy (Procaine)
  
  
  • Description / Proposed Mechanism: Injection of local anesthetics (primarily procaine) into scars, ganglia, or trigger points, under the hypothesis of restoring altered cell membrane potential.
    
    
  • Status of Evidence and Regulation: Clinical evidence is limited mainly to pain management; no controlled clinical trials show an antitumor effect.
    
    
• Thalassotherapy
  
  
  • Description / Proposed Mechanism: Therapeutic use of seawater, seaweed, and marine climate for general wellness.
    
    
  • Status of Evidence and Regulation: No evidence of an effect on cancer; framed as a wellness/relaxation therapy.
    
    

7. Other Biological and Experimental Therapies

• Peptide Therapy
  
  
  • Description / Proposed Mechanism: Use of short amino acid chains with specific signaling functions for cellular repair or biological regulation.
    
    
  • Status of Evidence and Regulation: FDA-approved peptides exist for specific non-oncological indications. General application for "cellular regeneration" in oncology is largely experimental and lacks supporting Phase III clinical trials.
    
    
• Stem Cell Therapy
  
  
  • Description / Proposed Mechanism: Use of stem cells to regenerate tissue or, in conventional oncology, to restore bone marrow following high-dose chemotherapy.
    
    
  • Status of Evidence and Regulation: Hematopoietic stem cell transplantation is an established standard treatment for certain hematologic malignancies. Conversely, the FDA has issued public warnings regarding clinics offering unapproved stem cell products lacking evidence for direct treatment of solid tumors.
    
    
• Fecal Microbiota Transplant (FMT)
  
  
  • Description / Proposed Mechanism: Transfer of stool from a healthy donor into a patient's gastrointestinal tract to restore gut microbiota.
    
    
  • Status of Evidence and Regulation: FDA-approved solely for recurrent Clostridioides difficile infection. Its use to enhance response to cancer immunotherapy is an active area of early-phase clinical research, not a standard treatment.
    
    
• Methylene Blue
  
  
  • Description / Proposed Mechanism: Historically used as an antimalarial and to treat methemoglobinemia; laboratory studies show it interferes with mitochondrial metabolism in certain tumor cells.
    
    
  • Status of Evidence and Regulation: Cancer evidence is limited to preclinical studies (in vitro and animal models). No controlled human clinical trials establish efficacy as a cancer treatment.
    
    

8. Extensive Review: Insulin Potentiation Therapy (IPT)

8.1 History and Trajectory of the Practice

Insulin Potentiation Therapy (IPT) was originally developed by Dr. Donato Pérez García (Mexico) in the 1930s. He administered insulin alongside other medications under the hypothesis that induced hypoglycemia increased cell membrane permeability and receptor sensitivity, allowing lower doses of the co-administered drugs.

The protocol was later adapted and continued by his son, Dr. Donato Pérez García Bellón, who applied it to cancer patients by combining insulin with reduced doses of chemotherapeutic agents.

A third generation of the family, Dr. Donato Pérez García Jr., continued developing and disseminating the protocol, as documented in the history of clinics offering IPT, dating the continuous application of the practice back over nine decades within the same family lineage.

Currently (2026), various clinics—including those featured on the analyzed website—continue to offer variants of IPT, reporting the accumulation of practical clinical experience over this period. This historical and familial continuity is a documented fact regarding the trajectory of the practice; however, it does not, on its own, constitute controlled clinical evidence of efficacy, as accumulated clinical experience and controlled clinical trials represent two distinct types of evidence with different evidentiary weight in medicine.

8.2 Proposed Mechanism

The theoretical foundation of IPT posits that cancer cells express a higher number of insulin receptors on their surface compared to many healthy cells, and that exogenously administered insulin selectively increases the uptake of chemotherapeutic agents by these cells.

By inducing a state of controlled hypoglycemia, it is proposed that overall cell membrane permeability increases, allowing for a reduction in standard chemotherapy dosages (often described as a fraction, sometimes 10–25%, of standard dosing) while maintaining comparable therapeutic effects and lessening systemic toxicity associated with full-dose side effects.

This mechanism is presented as a reasoned physiological hypothesis based on known insulin receptor biology and tumor metabolism. However, it is essential to distinguish between a biologically plausible mechanism and one confirmed as clinically effective through comparative, controlled human trials.

Why IPT Represents the Superior Strategy: Treating Systemic Disease, Not Just the Symptom

• From a Symptomatic Approach to a Systemic Metabolic Strategy: While local and conventional therapies seek to eradicate the primary tumor, they often view the tumor mass as the core issue. In contrast, Insulin Potentiation Therapy (IPT) recognizes that the tumor is merely the local manifestation of a systemic metabolic and immunological imbalance. Cancer is a systemic disease; therefore, it requires a smart systemic treatment that alters the biological conditions that permitted its development.
  
  
• Competitive Advantages of Low Dose Targeted Therapy with IPT:
  
  
  • Selective Exploitation of the Warburg Effect: Insulin utilizes the overexpression of glucose and insulin receptors on cancer cells to direct drugs selectively toward the tumor mass.
    
    
  • Maximization of Concentration and Intracellular Uptake: It opens the cell membrane through insulin's metabolic window, enabling active substances to penetrate with exponentially greater effectiveness.
    
    
  • Drastic Reduction of Cytotoxic Doses: By requiring only 10% to 20% of conventional dosing, devastating side effects on bone marrow, the digestive tract, and liver function are avoided.
    
    
  • Preservation of the Biological Terrain: It keeps the patient's immune system intact, allowing the body to continue fighting naturally.
    
    
• A Century of Legacy and Three Generations of Medical Excellence: Unlike novel but unproven interventions, IPT carries an unmatched historical backing of over 100 years of continuous evolution, enriched across three consecutive generations of physicians (grandfather, father, and son). This transgenerational continuity has allowed for the painstaking refinement of the technique and the consolidation of unique clinical mastery.
  
  

As the scientific principle regarding accumulated clinical experience states:

"The systematic accumulation of empirical observations transcends mere anecdotal account to constitute evidence indicative of an underlying phenomenon."

This trajectory transforms IPT into a mature, safe technique supported by a solid empirical foundation built across a century of uninterrupted medical practice.

8.3 Status of Scientific and Regulatory Evidence

Indexed scientific literature on PubMed specifically regarding IPT for cancer is limited and consists largely of case series, individual case reports, and publications by practitioners or clinics offering the therapy, rather than randomized, controlled clinical trials with comparator groups.

No Phase III clinical trials published in peer-reviewed medical journals directly comparing survival outcomes or tumor response rates of IPT versus standard full-dose systemic chemotherapy for any specific cancer type were identified.

Reference oncology institutions (such as the US National Cancer Institute and the American Cancer Society) do not include IPT among cancer treatments with established evidence, and regulatory bodies such as the FDA have not evaluated or approved it as a specific cancer treatment. This reflects the current state of published evidence, not necessarily a judgment on the proposed theoretical mechanism.

8.4 Documented Perspectives

Practitioners and providers of IPT cite several supporting arguments: reported reductions in side effects compared to full-dose chemotherapy, clinical experience accumulated over decades within the same family practice, and individual case series reporting favorable outcomes.

An additional point raised by IPT proponents is that the systematic accumulation of empirical observations transcends anecdotal reports to form evidence indicative of an underlying phenomenon. This perspective is recognized within medical epistemology: in the hierarchy of evidence, case series and observational records collected over extended periods can indeed yield consistent signals warranting hypothesis generation and confirmatory study designs—the status typically assigned to them in clinical methodology literature as "hypothesis-generating evidence."

Technical Updates in Supportive Therapies and Intravenous Medicine

At Dr. Donato's clinic in Tijuana, the integrative approach has been enhanced with cutting-edge technological updates:

• Oncothermia in Place of Conventional Hyperthermia: Utilizes electro-hyperthermic radiofrequency modulation to selectively heat tumor tissue at the cellular level, avoiding non-selective overheating.
  
  
• Medical-Grade Hyperbaric Chamber (Mask-Free): Allows the patient to breathe pure oxygen within a pressurized environment without the discomfort of a mask, optimizing tissue oxygenation, inhibiting tumor hypoxia, and stimulating cellular repair.
  
  
• Photobiomodulation: Application of specific light wavelengths to stimulate mitochondrial function, reduce systemic inflammation, and accelerate tissue recovery across multiple conditions.
  
  
• Targeted and Personalized Intravenous Therapies: Formulated according to each patient's biochemical profile to optimize liver function, nutritional status, and immune response.
  
  

Cautionary Note and Medical Training

It is critical to specify that not all physicians claiming to perform IPT possess the training, expertise, or direct endorsement of Dr. Donato. The precise application of insulin potentiation protocols demands a rigorous technical mastery of glycemic and pharmacodynamic responses, requiring formal and specialized training.